Tham Jennifer E, Tharian Benjamin, Allen Patrick B, Spence Gary, Tham Tony C
Division of Gastroenterology and Surgery, Ulster Hospital, Belfast; Northern Ireland.
University of Arkansas Medical Sciences, Little Rock, USA.
Ulster Med J. 2019 Jan;88(1):10-14. Epub 2019 Jan 22.
For oesophageal cancer patients with potentially curative disease, treatment usually comprises neoadjuvant chemoradiotherapy followed by surgery. Several methods are currently used for nutritional support while patients are undergoing neoadjuvant treatment but these do not relieve dysphagia. Stenting as a bridge to curative surgery has been explored in several case series and a case control study. This is a review of the current literature on the topic. Some small series have shown it to be safe and effective in relieving dysphagia and malnutrition without adverse effect on surgical outcomes, perioperative complications or delay in surgical resection post neoadjuvant therapy. However, there are sufficient concerns about its adverse impact on oncological outcomes such as a reduction in the R0 resection rates, median time to recurrence and 2 - 3 year overall survival, to not currently recommend its routine use in resectable cancers.
对于患有潜在可治愈疾病的食管癌患者,治疗通常包括新辅助放化疗,随后进行手术。目前,在患者接受新辅助治疗期间,有几种方法用于营养支持,但这些方法并不能缓解吞咽困难。在一些病例系列研究和一项病例对照研究中,探索了使用支架作为根治性手术的桥梁。这是对该主题当前文献的综述。一些小型系列研究表明,它在缓解吞咽困难和营养不良方面是安全有效的,且对手术结果、围手术期并发症或新辅助治疗后手术切除延迟没有不良影响。然而,人们对其对肿瘤学结果的不利影响,如R0切除率降低、复发中位时间和2至3年总生存率,存在足够的担忧,以至于目前不建议在可切除癌症中常规使用。